Jason Luke, MD
Enriched profileChief Medical Officer, Strand Therapeutics · Strand Therapeutics
Jason Luke is Chief Medical Officer, Strand Therapeutics at Strand Therapeutics. OpenAlex indexes 806 publications with 23,547 citations (h-index 64); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jason J. Luke, MD, is Chief Medical Officer, Strand Therapeutics. The public record shows 806 publications with 23,547 citations (h-index 64), centered on Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 31 companies, 3 NIH-funded awards (2020–2025).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Cancer Immunotherapy and Biomarkers
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 31 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 88 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 217.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Sponsor: Strand Therapeutics Inc.
- Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Sponsor: Falo, Louis, MD
Industry payments
Updated 27 Aug 2026
31 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20256 payments
- Genmab U.S., Inc.Program year20251 payment
- Shionogi IncProgram year20252 payments
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
100%l-Thyroxine100%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management
University of Pittsburgh at Pittsburgh
FY2025$485,600P30CA047904 - Immune Exclusion in Cancer Immunotherapy
University of Pittsburgh at Pittsburgh
FY2024$592,843R01DE031729 - Clinical Protocol and Data Management
University of Pittsburgh at Pittsburgh
FY2024$504,086P30CA047904
Congress activity
Updated 27 Aug 2026
154 congress contributions (2011–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.
Journal for immunotherapy of cancer
Clinical Trial2026 - IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.
Clinical cancer research
Clinical Trial2026 - Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.
Cancer research communications
Clinical Trial2025 - And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring.
Clinical cancer research
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Targeted agents and immunotherapies: optimizing outcomes in melanoma1,288 citations2017
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jason-luke-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jason-luke-0a86282a3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/jason-luke-11a38910
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
dailynews.ascopubs.org/do/podcast-advances-immunotherapy-melanoma-and-beyond
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗ - Other
oncologytube.com/jason-luke-md-jasonlukemd-upmchillmancc-immunotiil-immunotherapy-cancer-research-phase-iii-mk-3475-716-keynote-716
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗ - Other
upmc.com/media/news/051519-jason-luke
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →upmc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Rosalind Franklin University of Medicine and Science / Chicago Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗ - Internal Medicine Residency
Boston University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗ - Medical Oncology Fellowship
Memorial Sloan-Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗ - FACP - Fellow
American College of Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗ - FASCO - Fellow
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗
Editorial & leadership roles
journal and society appointments- Chief Medical Officer
Strand Therapeutics (current)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Director
Immunotherapy and Drug Development Center (IDDC), UPMC Hillman Cancer Center (prior)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗ - Associate Director for Clinical Research
UPMC Hillman Cancer Center (prior)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hillmanresearch.upmc.edu ↗
- Faculty affiliation
Harvard Medical School (prior, tied to Dana-Farber tenure)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →strandtx.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer